Mescaline's Different Neural Pathway, Sixty Years Late
A new brain scan of mescaline reveals what neuroscientists have suspected for years. It travels a different neural pathway than psilocybin or LSD.
The finding appeared in mid-2024 in a peer-reviewed study using PET imaging to map where mescaline binds in the brain compared to its synthetic cousins. It is genuinely novel neurochemistry — and it arrived roughly sixty years too late to matter.
Mescaline's obscurity isn't accidental. It's a replay of cannabis in the 1970s, when the DEA escalated enforcement right as cannabinoid research was beginning to move from chemistry into pharmacology.
Like cannabis, mescaline occurs naturally — in peyote and San Pedro cacti — which means no company can patent it. Pfizer cannot own mescaline the way Eli Lilly owned LSD's derivatives or the way modern labs own psilocybin analogues. Western pharmaceutical development didn't stall because the drug was uninteresting. It stalled because there was no monopoly to build.
Funding flows toward things you can own.
The Matthew effect in science says that credit flows toward those already credited, but underneath that observation lies something sharper. Funding flows toward things you can own. When the psychedelic renaissance began in the 2010s, venture capital and pharmaceutical companies didn't need to rediscover mescaline. They had psilocybin, which is synthetic in its research form, defensible in patent claims, and controllable in clinical trials. The indigenous knowledge. Peyote, San Pedro, centuries of ceremonial use — became a historical footnote rather than a research north star.
What's different now is that the funding gap has become visible. The 2024 brain scan exists precisely because universities and small research groups have begun mapping psychedelics without expecting a commercial endpoint. They're asking questions because the answer interests them, not because it leads to a product launch. But visibility doesn't reverse neglect. It only names what was already lost.
